Crocker Ventures is a venture capital investment firm established in 1998 and located in Salt Lake City, Utah. The firm focuses on investing in startups within the life sciences, healthcare, biotechnology, pharmaceuticals, medical devices, drug delivery, diagnostics, and information technology sectors. In addition to managing its portfolio of startup companies, Crocker Ventures is actively involved in managing intellectual property and exploring opportunities for the acquisition of new technologies. The firm aims to support innovation and growth within its targeted industries through strategic investments and management.
Kyte Learning specializes in providing personalized learning services for educational purposes through a comprehensive video library of relevant ed-tech training materials. The platform offers experience-based training courses developed by expert educators, focusing on both technical skills and practical classroom application strategies. Administrators can assign courses, track progress, and evaluate data to gain insights into the training being undertaken by teachers. This functionality supports educators in acquiring the necessary technology skills to achieve school objectives effectively.
iSchool Campus is a next generation Smart School provider, with offices in Utah and Washington D.C., that focuses on the individual student while empowering the inspiring teacher. iSchool designs and builds collaborative whole-school learning environments and integrates them with 21st century technology to promote innovation and foster imagination in the classroom. iSchool is committed to being ahead of the curve and at the cutting edge of learning technology and educator support.
Merrimack Pharmaceuticals is a biopharmaceutical company based in Cambridge, Massachusetts, founded in 1993. The company focuses on the discovery, design, and development of innovative therapies for diseases related to autoimmunity and cancer. Its notable products include MM-093, aimed at treating rheumatoid arthritis and psoriasis, and MM-121, a human monoclonal antibody designed to inhibit the ErbB3 receptor signaling. Merrimack employs a systems biology approach, utilizing multidisciplinary capabilities to create predictive computational models of biological systems, particularly in cell signaling networks. Additionally, the company engages in partnerships with third parties to enhance the commercialization of its therapeutics.
TMJ Implants (Golden, CO USA), is the recognized world leader in the design and manufacture of alloplastic implants for the treatment of temporomandibular joint disorders and injuries. The company designs and manufactures both stock and custom devices for partial and total joint replacement.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.